Aptevo Therapeutics Inc.
No SEC Form 4 filings for $APVO in the last 30 days.
See all $APVO insider activity →Aptevo Therapeutics (APVO) stock fell 17.3% pre-market to $2.15 despite reporting 93% clinical benefit rate in a trial for a treatment-resistant leukemia. The decline is attributed to 'sell the news' reaction, potential dilution from new shares, and bearish technical trends. The broader market showed mild gains, but not enough to offset APVO's challenges.
Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate in TP53-mutated AML patients using its mipletamig triplet, nearly doubling published outcomes for venetoclax and azacitidine. The Phase 1b/2 RAINIER trial is ongoing, with regulatory interaction planned for 1H27. APVO focuses on developing novel immunotherapies for cancer.
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each o
Over the past 7 days, alphai's AI scored 2 news stories mentioning APVO (Aptevo Therapeutics Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent APVO coverage spans corporate actions, technology and earnings.
Significant sell‑off despite positive data due to dilution overhang and sell‑the‑news dynamics.
Strong early efficacy could boost APVO's valuation and attract partnership or financing interest.
The filing confirms board composition and shareholder approvals, but contains no material financial impact.
Clinical readouts plus a defined Phase 2 path are the core near-term catalyst, while cash runway and non-dilutive funding shape risk.
This is a filing that accompanies quarterly financial results, but the scraped text does not include the actual numbers or guidance.
alphai scores every news story that mentions APVO with an AI model for sentiment and relevance, and aggregates insider trades from Aptevo Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aptevo Therapeutics (APVO) stock fell 17.3% pre-market to $2.15 despite reporting 93% clinical benefit rate in a trial for a treatment-resistant leukemia. The decline is attributed to 'sell the news' reaction, potential dilution from new shares, and bearish technical trends. The broader market showed mild gains, but not enough to offset APVO's challenges.
2 min readAptevo Therapeutics (APVO) reported a 93% clinical benefit rate in TP53-mutated AML patients using its mipletamig triplet, nearly doubling published outcomes for venetoclax and azacitidine. The Phase 1b/2 RAINIER trial is ongoing, with regulatory interaction planned for 1H27. APVO focuses on developing novel immunotherapies for cancer.
2 min readAptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each o
1 min readAptevo Therapeutics (NASDAQ:APVO) reported 2Q26 financial results and a business update. The company said mipletamig’s RAINIER Phase 1b/2 trial showed 87% clinical benefit and 81% remission in 31 evaluable unfit frontline AML patients, with dose optimization nearing completion and Phase 2 interaction expected in 1Q27. Aptevo appointed a new CSO, received a $1.5M non-dilutive grant for APVO451, and entered a 50/50 Niowave radiopharmaceutical collaboration. Cash was $9.8M at June 30, 2026.
6 min readAptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non
2 min readAptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds SEATTLE, WASHINGTON / ACCESSWIRE / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company develo
4 min readAptevo Therapeutics (NASDAQ:APVO) said it will induce holders to exercise existing common warrants for cash at a $4.03 exercise price, issuing inducement warrants for up to 1,274,610 shares. Separately, it plans a PIPE selling up to 861,708 shares (or pre-funded warrants) plus common warrants for up to 4,308,540 shares, also at $4.03. Gross proceeds total about $4.5 million, for working capital.
2 min readAptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001671584 false 0001671584 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
4 min readAptevo Therapeutics (Nasdaq:APVO) and Niowave announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Aptevo will supply multispecific targeting assets starting with Nectin-4; Niowave will provide radioisotopes and manufacturing, including Actinium-225. At closing, Niowave made an at-the-market equity investment for a 7.9% stake, potentially rising to 19.99% via warrant exercises.
4 min readAptevo Therapeutics (NASDAQ: APVO) detailed its bispecific cancer pipeline and clinical trial data for its lead acute myelogenous leukemia (AML) candidate, mipletamig, in its latest 10-K filing. Mipletamig, a CD123xCD3 T-cell engager, demonstrated an 86% clinical benefit rate and no cytokine release syndrome in frontline AML patients during the RAINIER trial. The company is also advancing ALG.APV-527 for solid tumors, as well as six preclinical candidates leveraging its ADAPTIR and ADAPTIR-FLEX platforms.
3 min read
